EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response

Anja Sofie Petersen iD, Mads Barloese, Nunu Lund iD, Adam Friis Pedersen, Marie-Louise Kulas Søborg, Mona Ameri Chalmer iD, Ida Callesen, Bendik Slagsvold Winsvold iD, John-Anker Zwart, DBDS Genomic Consortium, Sisse Rye Ostrowski, Ole Birger Pedersen und 5 weitere

European Journal of Neurology · 2023

DOI: 10.1111/ene.15736 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Anja Sofie Petersen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Danish Headache Centre, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, Denmark. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Cluster Headache. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lundbeckfonden, TrygFonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose The response to cluster headache treatments has a high interindividual variation. To date, treatment response has only been assessed by a candidate gene approach and no investigations into metabolic pathways have been performed. Our aim was to investigate the association between the polygenetic risk of cluster headache and treatment response to first‐line cluster headache treatments as well as known functional variants of CYP3A4 and the response to verapamil. Further, it was aimed to replicate previous single nucleotide polymorphisms found to be associated with treatment response in cluster headache and/or migraine.

Methods

In, 508 cluster headache patients diagnosed according to the International Classification of Headache Disorders were genotyped and participated in a semi‐structured interview to evaluate treatment response. Polygenetic risk scores were calculated by the effect retrieved from a meta‐analysis of the latest two genome‐wide association studies on cluster headache.

Results

Inferior treatment response to oxygen, triptans and verapamil is associated with chronicity of cluster headache were confirmed but no evidence was found that a response could be predicted by a high genetic risk of cluster headache. Likewise, verapamil response was not associated with functional variants of CYP3A4 . No support of the genetic variants previously reported to be associated with treatment response to triptans or verapamil was found.

Conclusion

The clinically relevant variation in treatment response for cluster headache was not influenced by genetic factors in the present study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3ACluster HeadacheHumansGenome-Wide Association StudyTryptaminesVerapamil

Stichwörter der Autor:innen

cluster headachecytochrome P450 3Aoxygenpolygenetic risk scoresumatriptanverapamil

Substanzen

Cytochrome P-450 CYP3ATryptaminesVerapamilCYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Danish Headache Centre, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Division of Clinical Neuroscience, Department of Research and Innovation, Oslo University Hospital, Oslo, Norway.
  • Department of Neurology, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

ORCID-Profile: Anja Sofie Petersen, Nunu Lund, Mona Ameri Chalmer, Bendik Slagsvold Winsvold, Malene Bredahl Hansen

Förderung

  • Lundbeckfonden
  • TrygFonden

Zitieren

APA

Petersen, A. S., Barloese, M., Lund, N., Pedersen, A. F., Søborg, M. K., Chalmer, M. A., Callesen, I., Winsvold, B. S., Zwart, J. A., DBDS Genomic Consortium, Ostrowski, S. R., Pedersen, O. B., Sellebjerg, F., Søndergaard, H. B., Hansen, M. B., Jensen, R. H., & Hansen, T. F. (2023). Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response. European Journal of Neurology. https://doi.org/10.1111/ene.15736

Vancouver

Petersen AS, Barloese M, Lund N, Pedersen AF, Søborg MK, Chalmer MA, et al. Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response. European Journal of Neurology. 2023. doi:10.1111/ene.15736

BibTeX
@article{Petersen2023,
  author = {Petersen, Anja Sofie and Barloese, Mads and Lund, Nunu and Pedersen, Adam Friis and Søborg, Marie-Louise Kulas and Chalmer, Mona Ameri and Callesen, Ida and Winsvold, Bendik Slagsvold and Zwart, John-Anker and DBDS Genomic Consortium, DBDS Genomic Consortium and Ostrowski, Sisse Rye and Pedersen, Ole Birger and Sellebjerg, Finn and Søndergaard, Helle Bach and Hansen, Malene Bredahl and Jensen, Rigmor Højland and Hansen, Thomas Folkmann},
  title = {Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15736}
}
Kostenlos starten →